Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Alli® 60 mg
DRUG
2 trials
Sponsors
GlaxoSmithKline
, Empros Pharma AB
Conditions
Obesity and Overweight
Overweight or Obese
Weight Loss
Phase 2
A Trial With EMP16 in Preparation for Late Phase Studies
Not yet recruiting
NCT06993428
Empros Pharma AB
Obesity and Overweight, Overweight or Obese
Start: 2025-05-20
End: 2025-07-29
Target: 39
Updated: 2025-05-28
Unknown Phase
Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
Withdrawn
NCT02141230
GlaxoSmithKline
Weight Loss
Start: 2015-12-31
End: 2016-02-29
Updated: 2016-06-30